In our study, our aim was to investigate whether Notch1 signalling could serve as a therapeutic target for TMZ‐resistant GBM cells by specifically targeting multidrug resistance genes, including MVP, MGMT, and ABCG2. This evidence concerns the gene MGMT and glioblastoma.